The benefits of Nervoderm

  • Clinically proven pain relief1
  • Non-drowsy
  • Targets nerve pain symptoms
    associated with PHN
  • Low risk of interaction with other pain medications
  • Patients in a clinical study averaged
    at least 50% pain relief after 7 days of use.1
  • Nervoderm patch can
    be cut to size
  • 12 hour relief

Understanding Nervoderm

Nervoderm is a product that contains the active ingredient lidocaine (lignocaine), which provides pain relief without
causing any numbness. Nervoderm works by preventing the damaged nerves from sending painful
messages to the brain. Lidocaine absorbs continuously into the skin to help provide relief from nerve pain.*

Clinically proven relief from nerve pain associated with PHN1–3

In a clinical study where patients used Nervoderm:1

  • On average, after one week of use, pain levels were halved.
  • Average pain levels continued to decrease after 2-4 weeks of use.
  • Nearly 60% of patients had moderate to complete improvement of their pain after 4 weeks of treatment.

Nervoderm reduced pain* initially and over time2

Nervoderm reduced pain* initially and over time2

Pain measured on an 11-point scale, from no pain to worst pain possible.
Adapted from Rehm S et al. 2010.2

Long-term nerve pain* relief with Nervoderm3

  • In a long-term clinical trial, patients used Nervoderm for up to 4 years and achieved 'moderate to a lot' of pain relief, which was maintained over the 4 year period.3

If a lot of pain persists after using Nervoderm for 2 to 4 weeks, see your doctor or pharmacist.
Continue using Nervoderm for as long as your doctor or pharmacist tells you.

*Associated with medically diagnosed post-herpetic neuralgia (PHN).

Always read the label. Follow the directions for use. If symptoms persist, talk to your healthcare professional.

References: 1. Katz NP et al. Pain Med 2002;3(4):324–32. Results achieved in a clinical trial assessing reduction in pain intensity among patients with PHN using Nervoderm (up to 3 patches). Funded by Endo Pharmaceuticals. 2. Rehm S et al. Curr Med Res Opin 2010; 26(7):1607–19. Results achieved in an analysis of a trial which assessed pain relief in 88 patients with PHN using either Nervoderm (up to 3 patches) or the active comparator over 4-weeks. W-NRS = patients’ recalled worst pain in 24 hour period. Values are averages. Funded by Grunenthal GmbH. 3. Sabatowski R et al. Curr Med Res Opin 2012; 28(8):1337–46. Results achieved in a 3-year extension trial assessing pain relief in patients with PHN using Nervoderm (up to 3 patches). Funded by Grünenthal GmbH.